A Phase 2, Open-label, Single-arm, Efficacy and Safety Study of MDV3100 in Patients With Hormone-naïve Prostate Cancer
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The proportion of subjects with a PSA response
A PSA response is defined as a decline from baseline in PSA level of 80% or greater at week 25
Day 169
No
Use Central Contact
Study Director
Astellas Pharma Europe BV
Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment
9785-CL-0321
NCT01302041
April 2011
December 2013
Name | Location |
---|